This report updates previous reviews that were conducted as part of the third and fourth International Workshops on Genetic Toxicology Testing of micronucleus (MN) assays in rodent tissues other than bone marrow. Tissues discussed here are liver, lung, skin, colon, spleen, testes and foetal/neonatal tissues with transplacental exposure. Previous reviews have been updated to include literature published after 2000. In addition to the previously described tissues, MN assays in bladder, buccal mucosal cells, stomach and vagina are also included. MN assays using tissues other than bone marrow are critical for risk assessments, for in situ evaluation and for studies of systemic genotoxic effects and modes of action. Protocols for the majority of assays in tissues other than bone marrow have not yet been well standardised and validated for regulatory application, and further development is needed to support regulatory studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/mutage/geq066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correct treatment of chronic osteomyelitis depends on proper identification of the bone-infecting microorganism, but it is difficult identify the specific etiology in previously treated patients and in those with implants. Small colony variants auxotrophyc for menadione had been related with false-negative results in culture of patient with chronic osteomyelitis, but menadione supplementation can increase bone culture performance. The purpose was to evaluate the effect of menadione supplementation on isolates in bone cultures, in a cohort of patients with osteomyelitis, Medellín- Colombia.
View Article and Find Full Text PDFThe purpose of this study was to evaluate the radiographic outcomes of distal chevron metatarsal osteotomy associated with lateral joint capsule split as only lateral soft tissue release in patients with symptomatic moderate and severe hallux valgus (HV) deformity. Ninety patients (103 feet) at our institution between January 2014 and December 2019 were included in the present retrospective study. Each patient was evaluated preoperatively and at final follow-up by means of weight bearing radiographs lateral and dorsoplantar views.
View Article and Find Full Text PDFElective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
J Clin Oncol
January 2025
Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA.
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma.
View Article and Find Full Text PDFWild-type bone marrow cells repopulate tissue resident macrophages and reverse the impacts of homozygous CSF1R mutation.
PLoS Genet
January 2025
Mater Research Institute-University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, Australia.
Adaptation to existence outside the womb is a key event in the life of a mammal. The absence of macrophages in rats with a homozygous mutation in the colony-stimulating factor 1 receptor (Csf1r) gene (Csf1rko) severely compromises pre-weaning somatic growth and maturation of organ function. Transfer of wild-type bone marrow cells (BMT) at weaning rescues tissue macrophage populations permitting normal development and long-term survival.
View Article and Find Full Text PDFMultifunctional DNA-Collagen Biomaterials: Developmental Advances and Biomedical Applications.
ACS Biomater Sci Eng
January 2025
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida 32611, United States.
The complexation of nucleic acids and collagen forms a platform biomaterial greater than the sum of its parts. This union of biomacromolecules merges the extracellular matrix functionality of collagen with the designable bioactivity of nucleic acids, enabling advances in regenerative medicine, tissue engineering, gene delivery, and targeted therapy. This review traces the historical foundations and critical applications of DNA-collagen complexes and highlights their capabilities, demonstrating them as biocompatible, bioactive, and tunable platform materials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!